Thrivent Financial for Lutherans Has $2.47 Million Position in Prestige Consumer Healthcare Inc. $PBH

Thrivent Financial for Lutherans lessened its stake in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 19.2% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 39,554 shares of the company’s stock after selling 9,406 shares during the period. Thrivent Financial for Lutherans’ holdings in Prestige Consumer Healthcare were worth $2,468,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank acquired a new stake in shares of Prestige Consumer Healthcare in the 2nd quarter valued at $41,848,000. Tributary Capital Management LLC boosted its holdings in Prestige Consumer Healthcare by 157.3% in the third quarter. Tributary Capital Management LLC now owns 379,410 shares of the company’s stock valued at $23,675,000 after acquiring an additional 231,969 shares during the last quarter. Edgestream Partners L.P. acquired a new stake in Prestige Consumer Healthcare in the second quarter worth about $10,821,000. Neumeier Poma Investment Counsel LLC increased its position in Prestige Consumer Healthcare by 119.5% in the second quarter. Neumeier Poma Investment Counsel LLC now owns 222,495 shares of the company’s stock worth $17,766,000 after purchasing an additional 121,145 shares during the period. Finally, Goldman Sachs Group Inc. raised its holdings in Prestige Consumer Healthcare by 28.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 546,672 shares of the company’s stock worth $46,997,000 after purchasing an additional 120,965 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $66.25 on Wednesday. The stock has a market cap of $3.13 billion, a PE ratio of 17.53, a price-to-earnings-growth ratio of 2.06 and a beta of 0.43. The stock has a 50-day moving average of $63.43 and a 200-day moving average of $63.74. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93. Prestige Consumer Healthcare Inc. has a one year low of $57.25 and a one year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings data on Thursday, February 5th. The company reported $1.14 earnings per share for the quarter, missing the consensus estimate of $1.16 by ($0.02). Prestige Consumer Healthcare had a return on equity of 12.02% and a net margin of 16.90%.The firm had revenue of $283.44 million for the quarter, compared to the consensus estimate of $286.93 million. During the same period in the previous year, the business earned $1.22 EPS. The firm’s revenue was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. As a group, sell-side analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on PBH. Oppenheimer cut their target price on shares of Prestige Consumer Healthcare from $82.00 to $72.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 21st. Zacks Research raised shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research note on Monday, November 10th. Jefferies Financial Group cut their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating on the stock in a report on Friday, January 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Finally, Canaccord Genuity Group dropped their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Three research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Prestige Consumer Healthcare has a consensus rating of “Hold” and a consensus target price of $80.60.

Insider Activity

In related news, VP Jeffrey Zerillo sold 719 shares of the company’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $60.00, for a total value of $43,140.00. Following the completion of the sale, the vice president owned 42,329 shares in the company, valued at $2,539,740. This represents a 1.67% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 1.40% of the stock is owned by company insiders.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).